SEC Form 4 · accession 0002149973-26-000004
ARS Pharmaceuticals, Inc. · SPRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Margaret Ekins Smith
Officer — Chief Commercial Officer
Period of report
Sep 1, 2026
Accepted (ET)
Sep 2, 2026 · 5:27 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001671858
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $5.77 | Sep 1, 2026 | A | 1,001,738 | A | — | Aug 31, 2036 | Common Stock | 1,001,738 | 1,001,738 | D |
Explanation of responses
- F125% of the shares subject to the option vest on August 17, 2027, and the remaining shares will vest monthly thereafter over three years.